New First-Line Option for Advanced ALK-Positive Lung Cancer

Published Date: 20 Dec 2024

In randomized study, ensartinib doubled PFS versus first-generation ALK inhibitor

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

2.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

3.

New First-Line Option for Advanced ALK-Positive Lung Cancer

4.

Getting ahead of head and neck cancer

5.

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot